ArticleDiscover nano2026
Spatially distributed bFGF and VEGFA gene delivery to tendon and peritendinous tissues enhances early tendon healing.
Article in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Tendon healing is limited by inadequate vascularity and low cellularity within the tendon, whereas surrounding peritendinous tissues include vascular, stromal, and extrinsic reparative cells. Building on prior work involving tendon-only co-delivery of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor A (VEGFA), this study investigated whether spatially expanding gene delivery to both the tendon and adjacent peritendinous subcutaneous tissue would enhance early repair. PLGA/PEI nanoparticle complexes carrying bFGF and VEGFA plasmids were characterized for morphology, particle size, plasmid complexation, surface charge, and in vitro release, with local reporter expression assessed in vivo. Therapeutic effects were evaluated in chicken digital flexor tendon and rat Achilles tendon injury models through non-injection, tendon-only, peritendinous subcutaneous-only, and combined injection groups. The complexes demonstrated effective plasmid complexation, sustained release, and detectable local EGFP reporter expression within both tissue compartments. Combined injection significantly increased the ultimate strength of chicken tendons at 2, 4, and 6 weeks, and rat Achilles tendons at 2 weeks, compared to non-injection controls; tendon-only injection did not yield similar improvements in early strength. Higher total local bFGF and VEGFA protein levels, more visually prominent Ki-67-positive staining and CD31-positive vascular structures, together with qualitatively more organized collagen morphology. These results indicate that expanding gene expression from the tendon proper to the tendon-peritendinous microenvironment can mitigate an early limitation of tendon-only delivery, supporting the concept of enhanced dual-compartment delivery, though dose-matched studies are needed to establish synergy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.